PhaseBio Pharmaceuticals IncGrey Market:PHASQ
- LAST PRICE0.0397
- TODAY'S CHANGE (%)0.0197 (98.5000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0200 / 0.0200
- Day Range
- 52 Week Range
- Volume27,054
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PHASQ |
|---|---|---|
| 09:32 ET | 9977 | 0.02 |
| 09:35 ET | 2000 | 0.0131 |
| 10:42 ET | 3330 | 0.0397 |
| 11:12 ET | 300 | 0.0132 |
| 11:21 ET | 1000 | 0.0133 |
| 12:12 ET | 2000 | 0.02115 |
| 12:35 ET | 1000 | 0.0136 |
| 03:19 ET | 7415 | 0.0397 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
PhaseBio Pharmaceuticals Inc | 997.2K | 0.0x | --- |
Rosetta Genomics Ltd | 590.0 | 0.0x | --- |
PolarityTE Inc | 5.7M | -0.2x | --- |
Medicure Inc | 9.6M | 4.7x | --- |
NovaBay Pharmaceuticals Inc | 4.4M | -0.4x | --- |
International Stem Cell Corp | 1.6M | -2.5x | --- |
Company Information
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on the development and commercialization of therapies for cardiopulmonary diseases. The Company’s product pipeline includes Bentracimab (PB2452), PB6440 (for treatment-resistant Hypertension), pemziviptadil (PB1046), GLP2-ELP and CNP-ELP. The Company conducting REVERSE-IT, its pivotal Phase III clinical trial of bentracimab. PB2452 is a novel recombinant human monoclonal antibody antigen-binding fragment, designed to reverse the antiplatelet activity of ticagrelor in the event of major bleeding. PB6440 is an oral selective aldosterone synthase inhibitor for treatment of resistant hypertension. Pemziviptadil (PB1046), is a novel, subcutaneously-injected VIP analogue, which is a recombinant fusion protein composed of VIP and its proprietary ELP technology. ELP technology platform is a growth engine for additional medicines for cardiovascular diseases.
Contact Information
- Headquarters
- 1 Great Valley Pkwy Ste 30MALVERN, PA, United States 19355-1423
- Phone
- 610-981-6500
- Fax
- 302-531-3150
Executives
- Independent Chairman of the Board, Co-Founder
- Clay Thorp
- Chief Executive Officer, Director
- Jonathan Mow
- Principal Financial Officer
- Lawrence Perkins
- Senior Vice President, General Counsel, Company Secretary
- Kristophe Hanson
- Senior Vice President of Human Resources
- Glen Burkhardt
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $997.2K |
|---|---|
Revenue (TTM) | $818.0K |
Shares Outstanding | 49.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.31 |
EPS | $-2.13 |
Book Value | $-1.93 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 1.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -12,738.63% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
